I-DXd

BIOLOGICAL4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Esophageal Squamous Cell CarcinomaLung NeoplasmOesophageal Squamous Cell CarcinomaSmall Cell Lung Cancer Extensive Stage

Phase 1

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

RecruitingNCT06780111

Merck Sharp & Dohme LLCEsophageal Squamous Cell Carcinoma

Start: 2025-07-30End: 2032-01-04Target: 298Updated: 2026-03-31

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

RecruitingNCT07227597

Merck Sharp & Dohme LLCSmall Cell Lung Cancer Extensive Stage

Start: 2026-01-29End: 2030-12-30Target: 170Updated: 2026-03-30

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Not yet recruitingNCT07405151

Merck Sharp & Dohme LLCOesophageal Squamous Cell Carcinoma

Start: 2026-03-11End: 2028-06-12Target: 60Updated: 2026-02-12

Phase 2

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

RecruitingNCT06780098

Merck Sharp & Dohme LLCLung Neoplasm

Start: 2025-05-28End: 2032-03-02Target: 144Updated: 2026-04-01

Related Papers

KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).

Journal of Clinical Oncology2025-05-28